Related Experiment Videos
Incorporating economic evaluations into decision-making: the Ontario experience
1Institute for Clinical Evaluative Sciences, Division of General Internal Medicine, Sunnybrook and Women's Health Sciences Centre, and the Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. alaupacis@ices.on.ca
Medical Care
|August 2, 2005
Summary
The Drug Quality and Therapeutics Committee (DQTC) and Canadian Expert Drug Assessment Committee (CEDAC) inform drug reimbursement decisions. This article examines their processes and discusses key issues like bias and transparency.
Area of Science:
- Health Policy
- Pharmaceutical Policy
- Health Economics
Background:
- The Drug Quality and Therapeutics Committee (DQTC) and the Canadian Expert Drug Assessment Committee (CEDAC) are key advisory bodies.
- These committees provide recommendations for publicly funded outpatient drug plans in Ontario and Canada, respectively.
- Understanding their operations is crucial for pharmaceutical access and healthcare system management.
Purpose of the Study:
- To describe the organizational and decision-making processes of the DQTC and CEDAC.
- To identify and discuss critical issues impacting these committees' functions and recommendations.
Main Methods:
- Descriptive analysis of committee structures and processes.
- Discussion of challenges and considerations in drug reimbursement recommendations.
Main Results:
- The article details how the DQTC and CEDAC are organized and how they make decisions.
- Key issues such as potential bias in industry submissions, transparency, access programs, conditional listings, and price negotiations are highlighted.
Conclusions:
- The functioning of drug assessment committees involves complex processes and potential challenges.
- Addressing issues like bias and transparency is vital for equitable and effective drug reimbursement policies.